RxDoctor Payments Data

Robert Vonderheide

Medical Oncology · Philadelphia, PANPI 1902849219

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,065 of the $10,131 with a category attached, or 99.4%. 4 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 58.2% of the total. Reporting peaked in 2023 at $5,850 and has fallen 99.6% since, to $21 in 2025.

$10,131in general payments, 2019–2025

Across 6 payments — averaging $1688.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$6K
  • Bristol Myers Squibb$3K
  • EMD Serono Research & Development Institute, Inc.$1K
  • Lilly USA, LLC$21
$1,893,225in research payments, 2019–2025

Across 3 payments — averaging $631,075 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$1.9M

What the payments were for

  • Consulting fees$10,06599%
  • Food & beverage$661%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,131 in reported general payments places this provider in the 65th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania

Other medical oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →